Hypoglycemia Observed During Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Treated by Subcutaneous Insulin Injection

Ito, Hiroyuki; Abe, Mariko; Shinozaki, Masaru; Oshikiri, Koshiro; Yamashita, Hiroyuki; Nakashima, Mina; Takaki, Akifusa; Yukawa, Chizuko; Furusho, Masahide; Antoku, Shinichi; Mifune, Mizuo; Togane, Michiko

doi:10.1089/dia.2013.0034

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously investigated the frequency of hypoglycemia using the CGM in type 2 diabetic patients undergoing basal-bolus insulin therapy. Although hypoglycemia was observed in more than 50% of the subjects, it was significantly less frequent in the patients using more than 40% of basal insulin in the total insulin dose [ 26 ]. Tamaki et al.…”

Section: Discussionmentioning

confidence: 99%

A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study

Itoh

Tsugami

Ando

et al. 2018

Journal of Drug Assessment

Self Cite

View full text Add to dashboard Cite

Objective: We compared the clinical course of type 2 diabetic patients whose basal insulin preparations were replaced from insulin glargine (IGlar) 100 units/mL (U100) to IGlar biosimilar or IGlar 300 units/mL (U300).Methods: After propensity score matching, 34 patients whose basal insulin preparation was switched from IGlar U100 to IGlar biosimilar and 102 switched to IGlar U300 were observed for 6 months.Results: The HbA1c level and body weight did not change significantly after the replacement in the IGlar biosimilar or IGlar U300 groups. In the IGlar biosimilar group, the frequency of subjects who experienced hypoglycemia after the replacement (12%) was not different from before (12%). However, the frequency was significantly lower after the replacement (2%) than before (13%) in the IGlar U300 group. The change in the HbA1c level after the replacement showed a significant association with the HbA1c level at the baseline but not with the kind of IGlar. Hypoglycemia was frequently observed in subjects who had experienced hypoglycemia before the replacement.Conclusions: IGlar biosimilar and IGlar U300 induced similar HbA1c and body weight changes among type 2 diabetic patients. IGlar biosimilar is a suitable option for patients with a low risk for hypoglycemia.

show abstract

Section: Discussionmentioning

confidence: 99%

A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study

Itoh

Tsugami

Ando

et al. 2018

Journal of Drug Assessment

Self Cite

View full text Add to dashboard Cite

show abstract

Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring

Uemura

Okada

Torimoto

et al. 2018

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

show abstract

Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundWe investigated the trends in the clinical characteristics and prescriptions of type 2 diabetic patients with severe hypoglycemia because the prescription rate of antidiabetic agents has significantly changed recently.MethodsA total of 193 patients with type 2 diabetes with severe hypoglycemia induced by antidiabetic agents between 2008 and 2013 were divided into three groups based on the period of visit: 2008 - 2009, 2010 - 2011 and 2012 - 2013.ResultsWhile the proportion of patients with severe hypoglycemia using insulin (from 55% to 74%), biguanides (from 6% to 20%), glinides, and dipeptidyl peptidase-4 inhibitors significantly increased, those using sulfonylureas (from 45% to 20%) significantly decreased. Errors of drug use significantly increased as a trigger of hypoglycemia in recent years. The number of antidiabetic agents (from 1.9 ± 0.6 to 2.3 ± 0.7), non-diabetic agents (from 2.3 ± 2.4 to 4.3 ± 3.3), and total drugs prescribed were significantly higher in recent years among patients receiving insulin therapy.ConclusionsPolypharmacy especially in patients receiving insulin therapy and errors of drug use have increased in type 2 diabetic patients with severe hypoglycemia in recent years. Intensive education in the usage rule of drugs is considered to be important in order to prevent severe hypoglycemia.

show abstract

Hypoglycemia Observed During Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Treated by Subcutaneous Insulin Injection

Abstract: An excessive dose of bolus insulin might increase the duration of hypoglycemia, independently from the HbA1c levels, in patients with type 2 diabetes mellitus receiving subcutaneous insulin injection.

Cited by 3 publications

References 16 publications

A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study

A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study

Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring

Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013

Contact Info

Product

Resources

About